IDXG — Interpace Biosciences Share News
0.000.00%
Last trade - 00:00- $45.71m
- $43.06m
- $38.73m
Brief: Interpace Biosciences Q1 Revenue USD 9.032 Million
Interpace Biosciences' Q4 revenue falls 26% after PancraGEN discontinuation
Brief: Interpace Biosciences Q4 Revenue USD 9.224 Million
Interpace Biosciences Q3 revenue down
Brief: Interpace Biosciences Q3 Revenue USD 8.756 Million
Brief: Interpace Biosciences Q2 Revenue USD 9.232 Million
Brief: Interpace Biosciences Q1 Revenue USD 11.515 Million
Brief: Interpace Biosciences Q3 Revenue USD 12.295 Million
Brief: Interpace Biosciences Q2 Revenue USD 12.001 Million
Brief: Interpace Biosciences Q1 Revenue USD 10.273 Million
Brief: Interpace Biosciences Q4 Revenue USD 10.283 Million
Brief: Interpace Biosciences Q3 Revenue USD 9.078 Million
Brief: Interpace Biosciences Q2 Revenue USD 11.026 Million
Brief: Interpace Biosciences Announces Record First Quarter 2023 Financial And Business Results
Brief: Interpace Biosciences Announces Third Quarter 2022 Financial, Business Results
Brief: Interpace Biosciences Announces Q1 2022 Financial And Business Results
Brief: Delisting Of Securities Of Interpace Biosciences, Inc., Francesca's Holdings Corporation, And Wins Finance Holdings Inc. From Nasdaq Stock Market
Brief: Interpace Biosciences Announces Impending Delisting From Nasdaq
Brief: Interpace Biosciences Announces Path Forward In Letter To Shareholders